Antibe Therapeutics Inc (ATE.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
(Values in thousands)
| 12-2023 | 09-2023 | 06-2023 | 03-2023 | 12-2022 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 11,339 | 4,143 | 8,793 | 6,755 | 10,529 |
| Marketable Securities | 13,567 | 23,733 | 25,514 | 32,137 | 31,826 |
| Receivables | 1,504 | 1,595 | 1,500 | 1,615 | 678 |
| Other current assets | 0 | 0 | 0 | 0 | 875 |
| TOTAL | $28,095 | $31,099 | $37,777 | $41,546 | $44,526 |
| Non-Current Assets | |||||
| Intangibles | 26,352 | 26,352 | 26,352 | 26,352 | 26,352 |
| Other Non-Current Assets | 1,915 | 2,754 | 2,708 | 2,663 | 2,851 |
| TOTAL | $28,267 | $29,106 | $29,060 | $29,015 | $29,203 |
| Total Assets | $56,362 | $60,205 | $66,837 | $70,561 | $73,729 |
| Liabilities | |||||
| Current Liabilities | |||||
| TOTAL | $2,794 | $2,865 | $4,410 | $2,764 | $2,835 |
| Non-Current Liabilities | |||||
| TOTAL | $27,631 | $27,631 | $27,631 | $27,631 | $27,631 |
| Total Liabilities | $30,425 | $30,496 | $32,041 | $30,395 | $30,466 |
| Shareholders' Equity | |||||
| Common Shares | 141,607 | 141,582 | 141,581 | 141,489 | 140,865 |
| Retained earnings | -145,498 | -141,285 | -136,277 | -130,491 | -126,943 |
| Other shareholders' equity | 10,264 | 10,264 | 10,264 | 10,264 | 10,264 |
| TOTAL | $25,937 | $29,709 | $34,796 | $40,166 | $43,263 |
| Total Liabilities And Equity | $56,362 | $60,205 | $66,837 | $70,561 | $73,729 |